 study interleukin vs lymphokine-activated killer cells treatment melanoma renal cell cancer purpose study efficacy safety continuous-infusion interleukin regimen patients metastatic melanoma renal cell cancer contribution lymphokine-activated killer cells patients lymphokine-activated killer cells Twenty-three patients renal cell carcinoma melanoma protocol objective responses assessable patients renal cell carcinoma melanoma patients progressive disease cycle weekly continuous-infusion Grade II toxic reactions fever rash anorexia gain common treated Significant vivo stimulation lymphokine-activated killer natural killer cell activity patients continuous-infusion regimen lymphokine-activated killer cells ineffective treatment melanoma renal cell carcinoma